In a separate editorial, Holden Thorp, the publications editor-in-chief, noted that these drugs have raised more questions than they have answereda hallmark of a true breakthrough.[1] More research is needed into the potential side effects of the long-term use of these drugs, for example, and fears are growing that patients will abuse GLP-1 agonists, taking them when they arent clinically necessary
BPC-157 is the only peptide that can be administered orally, and as such maintains its integrity and effectiveness in the extreme acidity of the gut
Antioxidant activity and protective effects of Alcalase-hydrolyzed soybean hydrolysate in human intestinal epithelial Caco-2 cells
Patent in 2013 and there are other patents pending
For a deeper dive into the conversion process, our dose conversion chart is the most comprehensive reference available
10.1016/j.biopsych.2015.01.005 322 MinterM